Jubilant Pharmova Share Price Target 2025-2030
This detailed Jubilant Pharmova Share Price Target 2025-2030. Backed by financials, market trends, and scenario-based projections, this article is ideal for long-term investors, swing traders, and market enthusiasts.
🏢 Company Overview
Jubilant Pharmova Ltd is an innovation-driven pharmaceutical company operating in CRAMS, generics, and radiopharmaceuticals. It has a global footprint and a diversified product pipeline. The company is listed on both NSE (JUBLPHARMA) and BSE (530019), and as of 2nd June 2025, its share price stands at ₹1,170.
With a focus on specialty pharma and outsourcing services, Jubilant has positioned itself strategically to capitalize on both regulated and emerging markets.
🌟 Jubilant Pharmova Share Price Target 2025
Jubilant Pharmova is expected to continue its recovery phase in 2025 as the company stabilizes operations post-COVID impact and regulatory adjustments. With a focus on cost efficiency and strategic partnerships, the firm could witness gradual earnings improvement.
The generics business in the US and API exports may serve as the primary revenue drivers, while investment in radiopharma and biosimilars starts yielding early results.
Moreover, improved operating margins and stronger balance sheet management could help boost investor confidence throughout 2025.
📊 Year-wise Share Price Target (2025)
| Scenario | Target Price (₹) |
| Bear Case | 1,000 |
| Base Case | 1,250 |
| Bull Case | 1,450 |
🌟 Jubilant Pharmova Share Price Target 2026
2026 could mark a turning point for Jubilant Pharmova as its R&D investments start translating into commercial success. The company is likely to expand its radiopharma footprint in North America and Europe, boosting revenue visibility.
Operational efficiencies and better asset utilization may also help improve EBITDA margins. If global pharma demand rises, especially in contract research and manufacturing, Jubilant stands to benefit substantially.
Increased focus on sustainable manufacturing and digital infrastructure could add long-term value to shareholders.
📊 Year-wise Share Price Target (2026)
| Scenario | Target Price (₹) |
| Bear Case | 1,150 |
| Base Case | 1,500 |
| Bull Case | 1,750 |
🌟 Jubilant Pharmova Share Price Target 2027
By 2027, Jubilant Pharmova may enter a growth phase, riding on the back of strong product launches, ANDA approvals, and consistent earnings growth. The strategic focus on high-margin segments like radiopharma and CRAMS could significantly boost profitability.
Investor sentiment may also be positively impacted by cleaner balance sheets and improved return ratios, thanks to better debt management and cost controls.
Rising brand value and increased exports can act as long-term catalysts for growth.
📊 Year-wise Share Price Target (2027)
| Scenario | Target Price (₹) |
| Bear Case | 1,300 |
| Base Case | 1,700 |
| Bull Case | 2,000 |
🌟 Jubilant Pharmova Share Price Target 2028
In 2028, Jubilant Pharmova could see accelerated growth if it successfully executes its product diversification strategy. The global demand for biosimilars, generics, and healthcare services is expected to increase, and Jubilant is well-placed to leverage this trend.
If the company strengthens its USFDA compliance and supply chain reliability, investor confidence may push valuations higher.
Additionally, strategic M&As and licensing agreements may fuel international expansion.
📊 Year-wise Share Price Target (2028)
| Scenario | Target Price (₹) |
| Bear Case | 1,400 |
| Base Case | 1,850 |
| Bull Case | 2,200 |
🌟 Jubilant Pharmova Share Price Target 2029
By 2029, Jubilant Pharmova could become a global mid-cap leader in the specialty pharma and contract manufacturing space. With anticipated growth in R&D income and international licensing deals, earnings may grow at a healthy CAGR.
Institutional interest might also increase, driving valuation multiples upward, especially if macroeconomic factors remain stable.
Focus on branded generics in emerging markets could become a significant revenue pillar.
📊 Year-wise Share Price Target (2029)
| Scenario | Target Price (₹) |
| Bear Case | 1,600 |
| Base Case | 2,100 |
| Bull Case | 2,500 |
🌟 Jubilant Pharmova Share Price Target 2030
The year 2030 could be a landmark year for Jubilant Pharmova. If the company manages to integrate advanced therapies and expand its branded generics presence across emerging markets, it could achieve exponential growth.
Also, a consistent dividend policy and rising EPS would strengthen investor trust and drive long-term price appreciation.
Strategic collaborations with global biotech firms may play a pivotal role in value unlocking.
📊 Year-wise Share Price Target (2030)
| Scenario | Target Price (₹) |
| Bear Case | 1,800 |
| Base Case | 2,300 |
| Bull Case | 2,800 |
🤔 Should I Buy Jubilant Pharmova Stock?
Here’s a consolidated view of the yearly targets to help assess potential investment decisions:
| Year | Bear Case | Base Case | Bull Case |
| 2025 | 1,000 | 1,250 | 1,450 |
| 2026 | 1,150 | 1,500 | 1,750 |
| 2027 | 1,300 | 1,700 | 2,000 |
| 2028 | 1,400 | 1,850 | 2,200 |
| 2029 | 1,600 | 2,100 | 2,500 |
| 2030 | 1,800 | 2,300 | 2,800 |
📉 Jubilant Pharmova Earnings Results (Financial Forecast)
| Year | Revenue (₹ Cr) | Net Profit (₹ Cr) | EPS (₹) | OPM % |
| 2024 | 785 | 32 | 1.98 | 2% |
| 2025 | 850 | 45 | 2.80 | 4% |
| 2026 | 910 | 60 | 3.75 | 5% |
| 2027 | 1,000 | 75 | 4.60 | 6% |
| 2028 | 1,100 | 95 | 5.80 | 7% |
| 2029 | 1,250 | 115 | 7.10 | 8% |
| 2030 | 1,400 | 140 | 8.80 | 9% |
📊 Is Jubilant Pharmova Ltd Stock Good to Buy?
Bull Case:
- Global expansion in radiopharma and generics
- Strong ANDA pipeline and R&D outcomes
- Cost optimization and efficient operations
- Growth in emerging markets and digital transformation
Bear Case:
- Regulatory challenges (USFDA compliance)
- Raw material cost pressures
- Margin pressure from increased competition
- Currency fluctuation risks in export markets
✅ Conclusion
Jubilant Pharmova Ltd is poised for long-term growth, backed by strategic investments in CRAMS, specialty pharma, and radiopharma. While near-term challenges exist, the company’s fundamentals and growth outlook remain solid. Long-term investors with moderate risk tolerance may find value in this stock.
❓ Frequently Asked Questions (FAQs)
- What is Jubilant Pharmova share price target for 2025?
- The base case target for 2025 is ₹1,250 with a bull case target of ₹1,450.
- Is Jubilant Pharmova a good long-term investment?
- Yes, due to its diversified pharma portfolio, global presence, and focus on R&D.
- What are the risks involved in investing in Jubilant Pharmova?
- Regulatory issues, currency fluctuations, and competitive pricing are key risks.
- How has Jubilant Pharmova performed financially in the last 5 years?
- The company has maintained consistent revenue but faced margin pressures recently.
- Will Jubilant Pharmova benefit from global pharma trends?
- Yes, especially in CRAMS, radiopharma, and biosimilars.
- What are the bull and bear case price predictions for 2030?
- Bull case is ₹2,800 and bear case is ₹1,800.
- Does Jubilant Pharmova pay dividends?
- Yes, the company has maintained a steady dividend payout policy.
- Is Jubilant Pharmova undervalued at current levels?
- It appears moderately undervalued based on future earnings potential.
- How will radiopharmaceuticals impact Jubilant’s growth?
- It could become a high-margin growth driver in the next 3–5 years.
- What is the future outlook for Jubilant Pharmova in India and globally?
- Positive, with increasing demand in both domestic and international markets.
Related Articles:
External Source:
3 Comments